Literature DB >> 17332141

Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart.

Ka Young Chung1, Jeffery W Walker.   

Abstract

Endothelin-1 (ET-1) regulates contractility and growth of the mammalian heart by binding endothelin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) G-protein-coupled receptors. To identify growth signaling pathways associated with ET-1 receptors in adult myocardium, a combined immunoprecipitation/proteomic analysis was performed. Signaling proteins believed to function downstream of ET(A) such as Galpha(q), phospholipase C-beta1, protein kinase C (PKC) epsilon, and PKCdelta were identified in immunoprecipitates of ET(A) by matrix-assisted laser desorption ionization/time of flight mass spectrometry. Also prominent were the growth factor receptor tyrosine kinases erbB2 and erbB4 and their downstream growth signaling effectors phosphoinositide-3 kinase (PI3 kinase), Akt, Raf-1, mitogen-activated protein kinase kinase (MEK), and extracellular signal-regulated kinase (Erk). Western blot analysis confirmed coimmunoprecipitation of erbB2/4, PI3 kinase, and Akt with ET(A), and confocal microscopy revealed their colocalization in cardiac transverse tubules (T-tubules). The erbB4 receptor ligand neuregulin-1beta (NRG1beta) promoted erbB2/4 tryosine phosphorylation and Akt serine phosphorylation in ventricular myocytes, whereas treatment with ET-1 did not. This observation argues against ET-1 growth signaling occurring via erbB2/4 transactivation in adult myocardium. ET-1 did, however, stimulate Erk1/2 phosphorylation and substantially blunted several NRG1beta-mediated actions, including erbB2/4 phosphorylation, serine phosphorylation of Akt, and negative inotropy. This inhibitory cross-talk between ET(A) and erbB2/4-Akt pathways was mimicked by a phorbol ester and blocked by pharmacological inhibition of PKC or MEK/Erk. The proteomic analysis and subsequent investigation of receptor cross-talk indicate that growth signaling between ET(A) and erbB pathways is fundamentally different in adult versus neonatal cardiac myocytes. The results may be relevant to cardiomyopathies associated with 1) prolonged exposure to ET-1; 2) degeneration of T-tubules; and 3) therapies targeted at erbB2 inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332141     DOI: 10.1124/mol.106.027599

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Authors:  Douglas B Sawyer; Xuyang Peng; Billy Chen; Laura Pentassuglia; Chee Chew Lim
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

Review 2.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

3.  Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells.

Authors:  Mandi M Hopkins; Ze Liu; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2016-07-29       Impact factor: 4.030

4.  A preferred AMPK phosphorylation site adjacent to the inhibitory loop of cardiac and skeletal troponin I.

Authors:  Raquel Sancho Solis; Ying Ge; Jeffery W Walker
Journal:  Protein Sci       Date:  2011-04-08       Impact factor: 6.725

5.  Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?

Authors:  Meejeon Roh; Sarki A Abdulkadir
Journal:  Cancer Biol Ther       Date:  2010-04-26       Impact factor: 4.742

6.  Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Sandy Eldridge; Liang Guo; Jodie Mussio; Mike Furniss; John Hamre; Myrtle Davis
Journal:  Toxicol Sci       Date:  2014-07-23       Impact factor: 4.849

Review 7.  Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.

Authors:  Andrew Geissler; Sergey Ryzhov; Douglas B Sawyer
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.